C12Q1/40

NANOALLERGENS AND USES THEREOF

Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.

NANOALLERGENS AND USES THEREOF

Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.

IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS
20230408529 · 2023-12-21 ·

The present invention relates to immunoassays for quantification of a high positively charged protein, such as a FGF-18 protein, in human synovial fluid sample.

IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS
20230408529 · 2023-12-21 ·

The present invention relates to immunoassays for quantification of a high positively charged protein, such as a FGF-18 protein, in human synovial fluid sample.

ALPHA AMYLASES IN FEED
20230407283 · 2023-12-21 ·

The present invention relates to a method for identifying a pepsin resistant alpha amylase enzyme for use in a feed supplement comprising: i) providing an alpha amylase enzyme; ii) admixing said alpha amylase with corn based feed and buffer o solution comprising a pepsin concentration of 9000 U/ml at pH 3, 40 C., 500 rpm for at least 120 minutes and analysing alpha amylase activity on said alpha amylase compared to a control sample; wherein said control sample differs in that no pepsin is o present during incubation; and iii) selecting an alpha amylase enzyme which substantially maintains alpha amylase activity under the assay conditions; feed supplements and feedstuffs comprising a pepsin resistant alpha amylase and the use of pepsin resistant alpha amylases in feed.

ALPHA AMYLASES IN FEED
20230407283 · 2023-12-21 ·

The present invention relates to a method for identifying a pepsin resistant alpha amylase enzyme for use in a feed supplement comprising: i) providing an alpha amylase enzyme; ii) admixing said alpha amylase with corn based feed and buffer o solution comprising a pepsin concentration of 9000 U/ml at pH 3, 40 C., 500 rpm for at least 120 minutes and analysing alpha amylase activity on said alpha amylase compared to a control sample; wherein said control sample differs in that no pepsin is o present during incubation; and iii) selecting an alpha amylase enzyme which substantially maintains alpha amylase activity under the assay conditions; feed supplements and feedstuffs comprising a pepsin resistant alpha amylase and the use of pepsin resistant alpha amylases in feed.

METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Transmittance based system/kit for point-of-care quantification of biomarkers sample and use thereof

A transmittance based system/kit for point-of-care quantification of biomarker samples includes a stage supporting a detection unit, an optical transmittance unit and a signal processing unit. The detection unit comprising reactive substrate is capable of undergoing a specific biomarker sample interactive reaction and generating a quantifiable optical signal proportional to the concentration of the said biomarker sample wherein the intensity of the color varies with the concentration of the analyte in the bio-sample. The optical transmittance unit, comprises a sample stage integrated with the light source and a photodetector, converting quantifiable optical signal transmitted through the reagent coated substrate detection unit to electrical signals, a signal processing unit connected to the said optical transmittance unit transduces the analogue electrical signal into the digital display signal. The simple, single step, cost-effective easily disposable system/kit is useful for point-of-care detection of important biomarkers such as amylase, creatinine, albumin, among others.

Transmittance based system/kit for point-of-care quantification of biomarkers sample and use thereof

A transmittance based system/kit for point-of-care quantification of biomarker samples includes a stage supporting a detection unit, an optical transmittance unit and a signal processing unit. The detection unit comprising reactive substrate is capable of undergoing a specific biomarker sample interactive reaction and generating a quantifiable optical signal proportional to the concentration of the said biomarker sample wherein the intensity of the color varies with the concentration of the analyte in the bio-sample. The optical transmittance unit, comprises a sample stage integrated with the light source and a photodetector, converting quantifiable optical signal transmitted through the reagent coated substrate detection unit to electrical signals, a signal processing unit connected to the said optical transmittance unit transduces the analogue electrical signal into the digital display signal. The simple, single step, cost-effective easily disposable system/kit is useful for point-of-care detection of important biomarkers such as amylase, creatinine, albumin, among others.